SCHEMBL30470938

SCHEMBL30470938

CN1CC2CC(c3nc4cc(Br)ccc4s3)C2C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.37
PPARA Q07869 2/20 0.34
HRH3 Q9Y5N1 2/20 0.34
ADORA1 P30542 1/20 0.34
APP P05067 1/20 0.33
PDE10A Q9Y233 1/20 0.32
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32
TUBA4A P68366 1/20 0.32
TUBB4B P68371 1/20 0.32
TUBB3 Q13509 1/20 0.32
TUBB2A Q13885 1/20 0.32
TUBB8 Q3ZCM7 1/20 0.32
TUBA3E Q6PEY2 1/20 0.32
TUBA1A Q71U36 1/20 0.32
TUBA1C Q9BQE3 1/20 0.32
TUBB6 Q9BUF5 1/20 0.32
TUBB2B Q9BVA1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29347373 1.00 DYRK1A (0.37) DYRK1APPARAHRH3ADORA1APP
SCHEMBL29981485 0.84 DYRK1A (0.42) DYRK1APPARAHRH3ADORA1APP
SCHEMBL29347360 0.84 DYRK1A (0.42) DYRK1APPARAHRH3ADORA1APP
SCHEMBL25955540 0.84 DYRK1A (0.39) DYRK1APPARAHRH3ADORA1APP
SCHEMBL30470420 0.84 DYRK1A (0.39) DYRK1APPARAHRH3ADORA1APP
SCHEMBL25335120 0.82 DYRK1A (0.39) DYRK1APPARAHRH3ADORA1APP
SCHEMBL25957469 0.81 DYRK1A (0.39) DYRK1APPARAHRH3ADORA1APP
SCHEMBL30515019 0.81 DYRK1A (0.39) DYRK1APPARAHRH3ADORA1APP
Formaldehyde SCHEMBL25335277 0.81 DYRK1A (0.40) DYRK1APPARAHRH3ADORA1APP
SCHEMBL24367591 0.78 SNCA (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 US disclosed
EP-4188920-A1 PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS Tango Therapeutics, Inc. (US) 2023-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 DYRK1A 2974/4885PPARA 638/4885HRH3 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.